AstraZeneca's new cancer research chief José Baselga plans to prioritise drug discovery in early-stage cancer over advanced stages of the disease. one of the 30-plus drugs approved in the US for solid tumours since 2014 were for early-stage cancer. The pharmaceutical giant is due to start trials of a drug for early-stage breast cancer later this year. AstraZeneca's shift in focus comes after a number of patents for its top-selling drugs, such as cholesterol drug Crestor, expire.
AstraZeneca's new cancer research chief José Baselga plans to prioritise drug discovery in early-stage cancer over advanced stages of the disease. Only two of the 30-plus drugs approved in the US for solid tumours since 2014 were for early-stage cancer. The pharmaceutical giant is due to start trials of a drug for early-stage breast cancer later this year. AstraZeneca's shift in focus comes after a number of patents for its top-selling drugs, such as cholesterol drug Crestor, expire.